Clinical transplantation of a tissue-engineered airway

Paolo Macchiarini, Philipp Jungebluth, Tetsuhiko Go, M. Adelaide Asnaghi, Louisa E. Rees, Tristan A. Cogan, Amanda Dodson, Jaume Martorell, Silvia Bellini, Pier Paolo Parnigotto, Sally C. Dickinson, Anthony P. Hollander, Sara Mantero, Maria Teresa Conconi, Martin A. Birchall

Research output: Contribution to journalArticle

1058 Citations (Scopus)

Abstract

Background: The loss of a normal airway is devastating. Attempts to replace large airways have met with serious problems. Prerequisites for a tissue-engineered replacement are a suitable matrix, cells, ideal mechanical properties, and the absence of antigenicity. We aimed to bioengineer tubular tracheal matrices, using a tissue-engineering protocol, and to assess the application of this technology in a patient with end-stage airway disease. Methods: We removed cells and MHC antigens from a human donor trachea, which was then readily colonised by epithelial cells and mesenchymal stem-cell-derived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman with end-stage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. Findings: The graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months. The patient had no anti-donor antibodies and was not on immunosuppressive drugs. Interpretation: The results show that we can produce a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks of rejection. The findings suggest that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious clinical disorders. Funding: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, Spain; Charles Courtenay-Cowlin Fund, University of Bristol; UK Arthritis Research Campaign; and the James Tudor Foundation.

Original languageEnglish (US)
Pages (from-to)2023-2030
Number of pages8
JournalThe Lancet
Volume372
Issue number9655
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Tissue Transplantation
Bronchomalacia
Tissue Donors
Transplants
Biocompatible Materials
Bronchi
Tissue Engineering
Immunosuppressive Agents
Chondrocytes
Trachea
Mesenchymal Stromal Cells
Spain
Arthritis
Anti-Idiotypic Antibodies
Cultured Cells
Epithelial Cells
Quality of Life
Technology
Antigens
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Macchiarini, P., Jungebluth, P., Go, T., Asnaghi, M. A., Rees, L. E., Cogan, T. A., ... Birchall, M. A. (2008). Clinical transplantation of a tissue-engineered airway. The Lancet, 372(9655), 2023-2030. https://doi.org/10.1016/S0140-6736(08)61598-6

Clinical transplantation of a tissue-engineered airway. / Macchiarini, Paolo; Jungebluth, Philipp; Go, Tetsuhiko; Asnaghi, M. Adelaide; Rees, Louisa E.; Cogan, Tristan A.; Dodson, Amanda; Martorell, Jaume; Bellini, Silvia; Parnigotto, Pier Paolo; Dickinson, Sally C.; Hollander, Anthony P.; Mantero, Sara; Conconi, Maria Teresa; Birchall, Martin A.

In: The Lancet, Vol. 372, No. 9655, 2008, p. 2023-2030.

Research output: Contribution to journalArticle

Macchiarini, P, Jungebluth, P, Go, T, Asnaghi, MA, Rees, LE, Cogan, TA, Dodson, A, Martorell, J, Bellini, S, Parnigotto, PP, Dickinson, SC, Hollander, AP, Mantero, S, Conconi, MT & Birchall, MA 2008, 'Clinical transplantation of a tissue-engineered airway', The Lancet, vol. 372, no. 9655, pp. 2023-2030. https://doi.org/10.1016/S0140-6736(08)61598-6
Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE, Cogan TA et al. Clinical transplantation of a tissue-engineered airway. The Lancet. 2008;372(9655):2023-2030. https://doi.org/10.1016/S0140-6736(08)61598-6
Macchiarini, Paolo ; Jungebluth, Philipp ; Go, Tetsuhiko ; Asnaghi, M. Adelaide ; Rees, Louisa E. ; Cogan, Tristan A. ; Dodson, Amanda ; Martorell, Jaume ; Bellini, Silvia ; Parnigotto, Pier Paolo ; Dickinson, Sally C. ; Hollander, Anthony P. ; Mantero, Sara ; Conconi, Maria Teresa ; Birchall, Martin A. / Clinical transplantation of a tissue-engineered airway. In: The Lancet. 2008 ; Vol. 372, No. 9655. pp. 2023-2030.
@article{5058c2bb58b5425487cec1083e38884c,
title = "Clinical transplantation of a tissue-engineered airway",
abstract = "Background: The loss of a normal airway is devastating. Attempts to replace large airways have met with serious problems. Prerequisites for a tissue-engineered replacement are a suitable matrix, cells, ideal mechanical properties, and the absence of antigenicity. We aimed to bioengineer tubular tracheal matrices, using a tissue-engineering protocol, and to assess the application of this technology in a patient with end-stage airway disease. Methods: We removed cells and MHC antigens from a human donor trachea, which was then readily colonised by epithelial cells and mesenchymal stem-cell-derived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman with end-stage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. Findings: The graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months. The patient had no anti-donor antibodies and was not on immunosuppressive drugs. Interpretation: The results show that we can produce a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks of rejection. The findings suggest that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious clinical disorders. Funding: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Fondo de Investigaci{\'o}n Sanitaria, Spain; Charles Courtenay-Cowlin Fund, University of Bristol; UK Arthritis Research Campaign; and the James Tudor Foundation.",
author = "Paolo Macchiarini and Philipp Jungebluth and Tetsuhiko Go and Asnaghi, {M. Adelaide} and Rees, {Louisa E.} and Cogan, {Tristan A.} and Amanda Dodson and Jaume Martorell and Silvia Bellini and Parnigotto, {Pier Paolo} and Dickinson, {Sally C.} and Hollander, {Anthony P.} and Sara Mantero and Conconi, {Maria Teresa} and Birchall, {Martin A.}",
year = "2008",
doi = "10.1016/S0140-6736(08)61598-6",
language = "English (US)",
volume = "372",
pages = "2023--2030",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9655",

}

TY - JOUR

T1 - Clinical transplantation of a tissue-engineered airway

AU - Macchiarini, Paolo

AU - Jungebluth, Philipp

AU - Go, Tetsuhiko

AU - Asnaghi, M. Adelaide

AU - Rees, Louisa E.

AU - Cogan, Tristan A.

AU - Dodson, Amanda

AU - Martorell, Jaume

AU - Bellini, Silvia

AU - Parnigotto, Pier Paolo

AU - Dickinson, Sally C.

AU - Hollander, Anthony P.

AU - Mantero, Sara

AU - Conconi, Maria Teresa

AU - Birchall, Martin A.

PY - 2008

Y1 - 2008

N2 - Background: The loss of a normal airway is devastating. Attempts to replace large airways have met with serious problems. Prerequisites for a tissue-engineered replacement are a suitable matrix, cells, ideal mechanical properties, and the absence of antigenicity. We aimed to bioengineer tubular tracheal matrices, using a tissue-engineering protocol, and to assess the application of this technology in a patient with end-stage airway disease. Methods: We removed cells and MHC antigens from a human donor trachea, which was then readily colonised by epithelial cells and mesenchymal stem-cell-derived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman with end-stage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. Findings: The graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months. The patient had no anti-donor antibodies and was not on immunosuppressive drugs. Interpretation: The results show that we can produce a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks of rejection. The findings suggest that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious clinical disorders. Funding: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, Spain; Charles Courtenay-Cowlin Fund, University of Bristol; UK Arthritis Research Campaign; and the James Tudor Foundation.

AB - Background: The loss of a normal airway is devastating. Attempts to replace large airways have met with serious problems. Prerequisites for a tissue-engineered replacement are a suitable matrix, cells, ideal mechanical properties, and the absence of antigenicity. We aimed to bioengineer tubular tracheal matrices, using a tissue-engineering protocol, and to assess the application of this technology in a patient with end-stage airway disease. Methods: We removed cells and MHC antigens from a human donor trachea, which was then readily colonised by epithelial cells and mesenchymal stem-cell-derived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman with end-stage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. Findings: The graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months. The patient had no anti-donor antibodies and was not on immunosuppressive drugs. Interpretation: The results show that we can produce a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks of rejection. The findings suggest that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious clinical disorders. Funding: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, Spain; Charles Courtenay-Cowlin Fund, University of Bristol; UK Arthritis Research Campaign; and the James Tudor Foundation.

UR - http://www.scopus.com/inward/record.url?scp=57349176894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349176894&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)61598-6

DO - 10.1016/S0140-6736(08)61598-6

M3 - Article

C2 - 19022496

AN - SCOPUS:57349176894

VL - 372

SP - 2023

EP - 2030

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9655

ER -